Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Atherosclerosis and Chlamydia pneumoniae].

Mikkel M Larsen1, Birgitte Mørn, Paul L Andersen

  • 1Infektionsmedicinsk afdeling, Skejby Sygehus, Arhus Universitetshospital, DK-8200 Arhus N. mikkelml@ofir.dk

Ugeskrift for Laeger
|January 30, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Ugeskrift for laeger·2024
Same author

Redirector of Vaccine-induced Effector Responses (RoVER) for specific killing of cellular targets.

EBioMedicine·2023
Same author

Reply to "Post-COVID myopathy".

European journal of neurology·2022
Same author

Myopathy as a cause of fatigue in long-term post-COVID-19 symptoms: Evidence of skeletal muscle histopathology.

European journal of neurology·2022
Same author

Helminth products modulate innate immune recognition of nucleic acids in systemic lupus erythematosus.

Lupus·2022
Same author

Diagnostic performance, user acceptability, and safety of unsupervised SARS-CoV-2 rapid antigen-detecting tests performed at home.

International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases·2022

Chlamydia pneumoniae infection may be linked to atherosclerosis, but evidence is weakening. Antibiotic treatment shows a temporary protective effect on cardiovascular disease, though not currently recommended.

Area of Science:

  • Infectious diseases and cardiovascular health.
  • Microbial pathogenesis and atherosclerosis.
  • Pharmacological interventions for cardiovascular disease.

Context:

  • Chlamydia pneumoniae (C. pneumoniae) has been investigated for its potential role in atherosclerosis and thromboembolic events.
  • Existing evidence linking C. pneumoniae to cardiovascular disease (CVD) risk is diminishing, with no established causality.
  • The impact of antibiotic therapies on CVD outcomes remains an area of research.

Purpose:

  • To review the current evidence on the association between Chlamydia pneumoniae and cardiovascular disease.
  • To evaluate the effects of antibiotic treatment, particularly macrolides, on cardiovascular outcomes.
  • To assess the potential mechanisms behind any observed therapeutic effects.

Summary:

Related Experiment Videos

  • While Chlamydia pneumoniae has been implicated in atherosclerosis, the association appears to be weakening, and causality is not proven.
  • Epidemiological studies and randomized controlled trials suggest a transient protective effect of macrolide antibiotics on cardiovascular disease.
  • This effect may stem from both antibacterial and anti-inflammatory properties of macrolides.

Impact:

  • Current data do not support the use of antibiotics for treating cardiovascular disease.
  • Further large-scale, long-term trials are needed to better understand antibiotic effects on CVD, though they may not resolve the role of C. pneumoniae.
  • This research informs clinical practice regarding antibiotic use in the context of cardiovascular health.